ADMA Biologics
ADMA
10.14
-0.04
-0.39%
ADMA Biologics
US · ADMA
#2705 by market cap
Listed 1970
10.14
-0.04
-0.39%
Live - 5344 symbols - heartbeat 431s ago
· 2026-10-08 07:05
Pre-market
10.15
+0.10%
After-hours
10.14
0.00%
- Market cap
- 2.27B
- P/E (TTM)i
- 14.49
- P/Bi
- 5.57
- EPSi
- 0.60
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on ADMA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.4 percentage points.
Institutional ownership
- Held by institutions
- 91.64% +0.40pp
- Institutions
- 375 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund64.67%
Hedge Fund17.89%
Public Company3.43%
Individual/Insider1.89%
Private Company1.51%
Government Pension Fund1.50%
Family Office/Trust1.32%
VC/PE Fund1.11%
Other6.59%
Top holders as of 2026-06-30
BlackRock
17.12% · 38.36M sh
State Street Global Advisors
7.64% · 17.12M sh
Vanguard Capital Management, LLC
5.25% · 11.76M sh
Vanguard Portfolio Management, LLC
4.50% · 10.09M sh
Rubric Capital Management LP
4.17% · 9.34M sh
Capital Research
3.91% · 8.76M sh
First Trust Advisors L.P.
3.48% · 7.80M sh
Geode Capital Management, LLC
2.71% · 6.06M sh
Caligan Partners, LP
2.56% · 5.73M sh
D. E. Shaw & Co., L.P.
2.35% · 5.27M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Adam Grossman | Chief Executive Officer | 1.31% |
| Jerrold Grossman | Co-Founder & Vice Chairman of the Board | 0.25% |
| Young Kwon | Independent Director | 0.11% |
| Lawrence Guiheen | Independent Director | 0.08% |
| Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | 0.07% |
| Steven Elms | Independent Chairperson | 0.04% |
| Alison Finger | Director | 0.02% |
| Eduardo Salas | Director | 0.00% |
| Brad Tade | Vice President of Financial Operations | 0.00% |
| P. Terence Kohler | Chief Financial Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-23 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Sale to Issuer | -3,177 | $8.37 |
| 2026-07-15 | P. Terence Kohler | Chief Financial Officer | Other Acquisition | +85,130 | -- |
| 2026-07-15 | P. Terence Kohler | Chief Financial Officer | Other Derivative Acquisition | +136,363 | $8.81 |
| 2026-05-26 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +6,400 | $7.91 |
| 2026-05-11 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +12,500 | $8.01 |
| 2026-05-10 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +12,500 | $8.01 |
| 2026-03-31 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Sale to Issuer | -20,362 | $9.11 |
| 2026-03-16 | Lawrence Guiheen | Independent Director | Derivative Exercise and Sale | -30,000 | -- |
| 2026-03-16 | Lawrence Guiheen | Independent Director | Other Acquisition | +30,000 | -- |
| 2026-03-15 | Adam Grossman | Chief Executive Officer | Automatic Disposition | -6,000 | $15.16 |
| 2026-03-15 | Adam Grossman | Chief Executive Officer | Derivative Exercise and Sale | -15,000 | $5.40–15.16 |
| 2026-03-09 | Brad Tade | Vice President of Financial Operations | Intent to Sell (Form 144) | -50,026 | $15.81 |
| 2026-03-08 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Other Disposition | -91,266 | -- |
| 2026-03-08 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Derivative Exercise and Sale | -10,096 | $1.55–15.63 |
| 2026-03-06 | Adam Grossman | Chief Executive Officer | Sale to Issuer | -85,951 | $15.39 |
| 2026-03-06 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Sale to Issuer | -14,294 | $15.39 |
| 2026-03-05 | Aisling Capital Management LP | -- | Open Market Acquisition | +14,000 | $15.39–15.67 |
| 2026-02-25 | P. Terence Kohler | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Adam Grossman | Chief Executive Officer | Sale to Issuer | -54,858 | $15.18 |
| 2026-02-18 | Adam Grossman | Chief Executive Officer | Sale to Issuer | -24,793 | $16.32 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:05:07 · For reference only, not investment advice and not tailored to your situation.